Larry Robbins' Strategic Moves: CVS Health Corp Sees a -6.25% Portfolio Impact

Exploring the Latest 13F Filing from Glenview Capital Management

Larry Robbins (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights into his investment moves during this period. Glenview Capital Management, founded in 2000 by Larry Robbins (Trades, Portfolio), is a privately held investment management firm. Glenview manages assets split between two products: the Glenview Funds (long/short) and the Glenview Opportunity Funds (concentrated, opportunistic). Glenview is focused on delivering attractive absolute returns through an intense focus on deep fundamental research and individual security selection. Their investments are primarily focused on the U.S., with a smaller amount of exposure in Western Europe.

Warning! GuruFocus has detected 11 Warning Signs with CVS.Larry Robbins' Strategic Moves: CVS Health Corp Sees a -6.25% Portfolio Impact

Summary of New Buy

Larry Robbins (Trades, Portfolio) added a total of 10 stocks, among them:

The most significant addition was Dick's Sporting Goods Inc (NYSE:DKS), with 290,532 shares, accounting for 1.61% of the portfolio and a total value of $57.47 million. The second largest addition to the portfolio was Thermo Fisher Scientific Inc (NYSE:TMO), consisting of 100,000 shares, representing approximately 1.14% of the portfolio, with a total value of $40.55 million. The third largest addition was Surgery Partners Inc (NASDAQ:SGRY), with 1,529,225 shares, accounting for 0.95% of the portfolio and a total value of $33.99 million.

Key Position Increases

Larry Robbins (Trades, Portfolio) also increased stakes in a total of 11 stocks, among them:

The most notable increase was Meta Platforms Inc (NASDAQ:META), with an additional 70,830 shares, bringing the total to 115,934 shares. This adjustment represents a significant 157.04% increase in share count, a 1.47% impact on the current portfolio, with a total value of $85.57 million. The second largest increase was Global Payments Inc (NYSE:GPN), with an additional 523,209 shares, bringing the total to 4,316,892. This adjustment represents a significant 13.79% increase in share count, with a total value of $345.52 million.

Summary of Sold Out

Larry Robbins (Trades, Portfolio) completely exited 12 holdings in the second quarter of 2025, as detailed below:

Corteva Inc (NYSE:CTVA): Larry Robbins (Trades, Portfolio) sold all 1,392,104 shares, resulting in a -2.15% impact on the portfolio. Dun & Bradstreet Holdings Inc (NYSE:DNB): Larry Robbins (Trades, Portfolio) liquidated all 9,768,483 shares, causing a -2.15% impact on the portfolio.

Key Position Reduces

Larry Robbins (Trades, Portfolio) also reduced positions in 19 stocks. The most significant changes include:

Story Continues

Reduced CVS Health Corp (NYSE:CVS) by 3,750,000 shares, resulting in a -31.39% decrease in shares and a -6.25% impact on the portfolio. The stock traded at an average price of $65.61 during the quarter and has returned 14.21% over the past 3 months and 57.42% year-to-date. Reduced Universal Health Services Inc (NYSE:UHS) by 497,893 shares, resulting in a -56.11% reduction in shares and a -2.3% impact on the portfolio. The stock traded at an average price of $180.55 during the quarter and has returned -8.74% over the past 3 months and -0.26% year-to-date.

Portfolio Overview

At the second quarter of 2025, Larry Robbins (Trades, Portfolio)'s portfolio included 43 stocks, with top holdings including 15.84% in CVS Health Corp (NYSE:CVS), 14.45% in Tenet Healthcare Corp (NYSE:THC), 9.68% in Global Payments Inc (NYSE:GPN), 7.43% in Teva Pharmaceutical Industries Ltd (NYSE:TEVA), and 4.64% in ZoomInfo Technologies Inc (NASDAQ:GTM).

The holdings are mainly concentrated in 8 of the 11 industries: Healthcare, Technology, Industrials, Consumer Cyclical, Consumer Defensive, Communication Services, Financial Services, and Basic Materials.Larry Robbins' Strategic Moves: CVS Health Corp Sees a -6.25% Portfolio Impact

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.

View Comments